Europe Narcolepsy Market : Table of Contents

1. Introduction

1.1 Report Guidance

1.2 Market Segmentation

2. Executive Summary

2.1 Key Market Insights

2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research

3.2 Primary Research

3.2.1 Data Triangulation and Validation

4. Europe Narcolepsy Market Landscape

4.1 Overview

4.3 Ecosystem Analysis

4.3.1 List of Vendors in the Value Chain

5. Europe Narcolepsy Market – Key Market Dynamics

5.1 Market Drivers

5.2 Market Restraints

5.3 Market Opportunities

5.4 Future Trends

5.5 Impact of Drivers and Restraints

6. Europe Narcolepsy Market Regional Analysis

6.2 Europe Narcolepsy Market Revenue 2016-2027 (US$ Million)

6.3 Europe Narcolepsy Market Forecast Analysis

7. Europe Narcolepsy Market Analysis – by Type

7.1 Narcolepsy with Cataplexy

7.1.1 Overview
7.1.2 Narcolepsy with Cataplexy: Europe Narcolepsy Market – Revenue and Forecast, 2016-2027 (US$ Million)

7.2 Narcolepsy without Cataplexy

7.2.1 Overview
7.2.2 Narcolepsy without Cataplexy: Europe Narcolepsy Market – Revenue and Forecast, 2016-2027 (US$ Million)

7.3 Secondary Narcolepsy

7.3.1 Overview
7.3.2 Secondary Narcolepsy: Europe Narcolepsy Market – Revenue and Forecast, 2016-2027 (US$ Million)

8. Europe Narcolepsy Market Analysis – by Product

8.1 Central Nervous System Stimulants

8.1.1 Overview
8.1.2 Central Nervous System Stimulants: Europe Narcolepsy Market – Revenue and Forecast, 2016-2027 (US$ Million)

8.2 Sodium Oxybate

8.2.1 Overview
8.2.2 Sodium Oxybate: Europe Narcolepsy Market – Revenue and Forecast, 2016-2027 (US$ Million)

8.3 Antidepressants

8.3.1 Overview
8.3.2 Antidepressants: Europe Narcolepsy Market – Revenue and Forecast, 2016-2027 (US$ Million)

9. Europe Narcolepsy Market Analysis – by Distribution Channel

9.1 Hospital Pharmacies

9.1.1 Overview
9.1.2 Hospital Pharmacies: Europe Narcolepsy Market – Revenue and Forecast, 2016-2027 (US$ Million)

9.2 Retail Pharmacies

9.2.1 Overview
9.2.2 Retail Pharmacies: Europe Narcolepsy Market – Revenue and Forecast, 2016-2027 (US$ Million)

10. Europe Narcolepsy Market – Europe Analysis

10.1 Overview

10.2 Europe

10.2.1 Europe Narcolepsy Market Breakdown, by Key Country, 2019 and 2027 (%)
10.2.1.1 Europe Narcolepsy Market – Revenue and Forecast Analysis – by Country
10.2.1.1 UK: Europe Narcolepsy Market – Revenue and Forecast to 2027 (US$ Million)

10.2.1.1.1 UK: Europe Narcolepsy Market Breakdown, by Type
10.2.1.1.2 UK: Europe Narcolepsy Market Breakdown, by Product
10.2.1.1.3 UK: Europe Narcolepsy Market Breakdown, by Distribution Channel

10.2.1.2 Germany: Europe Narcolepsy Market – Revenue and Forecast to 2027 (US$ Million)

10.2.1.2.1 Germany: Europe Narcolepsy Market Breakdown, by Type
10.2.1.2.2 Germany: Europe Narcolepsy Market Breakdown, by Product
10.2.1.2.3 Germany: Europe Narcolepsy Market Breakdown, by Distribution Channel

10.2.1.3 France: Europe Narcolepsy Market – Revenue and Forecast to 2027 (US$ Million)

10.2.1.3.1 France: Europe Narcolepsy Market Breakdown, by Type
10.2.1.3.2 France: Europe Narcolepsy Market Breakdown, by Product
10.2.1.3.3 France: Europe Narcolepsy Market Breakdown, by Distribution Channel

10.2.1.4 Russia: Europe Narcolepsy Market – Revenue and Forecast to 2027 (US$ Million)

10.2.1.4.1 Russia: Europe Narcolepsy Market Breakdown, by Type
10.2.1.4.2 Russia: Europe Narcolepsy Market Breakdown, by Product
10.2.1.4.3 Russia: Europe Narcolepsy Market Breakdown, by Distribution Channel

10.2.1.5 Italy: Europe Narcolepsy Market – Revenue and Forecast to 2027 (US$ Million)

10.2.1.5.1 Italy: Europe Narcolepsy Market Breakdown, by Type
10.2.1.5.2 Italy: Europe Narcolepsy Market Breakdown, by Product
10.2.1.5.3 Italy: Europe Narcolepsy Market Breakdown, by Distribution Channel

10.2.1.6 Rest of Europe: Europe Narcolepsy Market – Revenue and Forecast to 2027 (US$ Million)

10.2.1.6.1 Rest of Europe: Europe Narcolepsy Market Breakdown, by Type
10.2.1.6.2 Rest of Europe: Europe Narcolepsy Market Breakdown, by Product
10.2.1.6.3 Rest of Europe: Europe Narcolepsy Market Breakdown, by Distribution Channel

11. Competitive Landscape

11.1 Heat Map Analysis

11.2 Company Positioning and Concentration

12. Industry Landscape

12.1 Overview

12.2 Market Initiative

12.3 Partnerships and Collaborations

12.4 Other Developments

13. Company Profiles

13.1 Teva Pharmaceutical Industries Ltd.

13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments

13.2 Jazz Pharmaceuticals plc

13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments

13.3 Arena Pharmaceuticals, Inc.

13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments

13.4 Graymark Healthcare, Inc.

13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments

13.5 Novartis AG

13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments

13.6 Takeda Pharmaceutical Company Limited

13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments

13.7 Mylan N.V.

13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments

13.8 BIOPROJET

13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments

13.9 Shionogi & Co., Ltd.

13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments

13.10 Ligand Pharmaceuticals, Inc

13.10.1 Key Facts
13.10.2 Business Description
13.10.3 Products and Services
13.10.4 Financial Overview
13.10.5 SWOT Analysis
13.10.6 Key Developments

14. Appendix

14.1 About Business Market Insights

14.2 List of Abbreviations

Europe Narcolepsy Market

Analysis and Forecasts By Type (Narcolepsy with Cataplexy, Narcolepsy without Cataplexy, and Secondary Narcolepsy); Product (Central Nervous System (CNS) Stimulants, Sodium Oxybate, and Antidepressants); Distribution Channel (Hospital Pharmacies and Retail Pharmacies) and Country